medigraphic.com

2003, Number 2

<< Back Next >>

Rev Fac Med UNAM 2003; 46 (2)

Contemporary views of osteoporosis

Zárate A, Hernández M, Morán C, Ángeles L

Language: Spanish
References: 14
Page: 49-51
PDF size: 32.22 Kb.


ABSTRACT

Osteoporosis has now been defined as a loss of the osseous micro-architecture that alters the quality of the bone making it susceptible to a fracture; therefore, the measurement of the quantity of mineralization is only one factor that is used along with others to determine the resistance or solidity of the bone. Bone densitometry should not be considered as a routine test but should be carried out when other fracture risks exist such as age, gender, smoking, body weight, and family and personal history of fractures. A low bone density indicates the risk of a fracture but the interpretation should be made taking into account other indices, as biochemical markers for osseous remodeling. Various pharmacological agents are used in the treatment of osteoporosis thereby allowing for individual treatment regimens to be created. These agents can be grouped into two categories: antiresorptives and anabolics. The decision to carry out diagnostic tests and choose the appropriate therapy are based on establishing a particular point of view.


REFERENCES

  1. Yeh SS, Phanumas D, Hafner A, Schuster MW. Risk factors for osteoporosis in a subgroup of elderly men in a veterans administration nursing home. J Investig Med 2002; 50: 452-457.

  2. Riggs BL. Overview of osteoporosis. West J Med 1991; 154: 63-77.

  3. Marshall D. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996; 312: 1254-1259.

  4. Frost HM. Emerging views about “osteoporosis”, bone health strength fragility, and their determinants. J Bone Miner Metab 2002; 20: 319-325.

  5. Consensus Development Statement . Who are candidates for prevention and treatment. Osteoporosis Int 1997; 7: 1-6.

  6. Nagata-Kobayashi S, Shimbo T, Fukui T. Cost-effectiveness analysis of screening for osteoporosis in postmenopausal Japanese women. J Bone Miner Metab 2002; 20: 350-357.

  7. Kamia JA. Diagnosis of osteoporosis and assessment of fracture risk. The Lancet 2002; 359: 1929-1936.

  8. Jiang Y, Li M, Xia W, Xing X, Yu W, Tiang J, Meng X, Zhou X. Alendronate in potsmenopausal women with osteopenia and osteoporosis: effects of bone mineral density during treatment and after withdrawal. Zhonghua Yi Xue Za Zhi 2002; 82: 1254-1256.

  9. Stejskal D, Zurek M, Bartek J, Jedelsky L, Ruzicka V. Osteoprotegerin of bone density. Biomed Pap Med Fac Palacky Olomouc Czech Repub. 2001; 145: 75-76.

  10. Zárate A, Hernández-Valencia M. Terapia de reemplazo hormonal en mujeres menopáusicas tratadas por cáncer mamario. Rev Med IMSS 2002; 40: 369-371.

  11. Nelson HD, Humphery LL, Nygren P, Teutsch SM, Allan JD. Postmenopausal hormone replacement therapy: scientific review. JAMA 2002; 288: 872-881.

  12. Srivastava M, Deal C. Osteoporosis in elderly: prevention and treatment. Clin Geriatr Med 2002; 18: 529-555.

  13. Feskanich D, Willet W, Colditz G. Walking and leisure-time activity and risk of hip fracture in postmenopausal women. JAMA 2002; 288: 2300-2306.

  14. Body JJ, Gaich GA, Scheele WH, Kulkarni PM, Miller PD, Peretz A, Dore RK, Correa-Rotter R, Papaioannou A, Cumming DC, Hodsman AB. A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2002; 87: 4528-4535.




2020     |     www.medigraphic.com